Logo do repositório

Percorrer por autor "Brown, James"

A mostrar 1 - 2 de 2
  • Diagnostic accuracy and predictive value of the QuantiFERON-TB gold plus assay for tuberculosis in immunocompromised individuals: a prospective TBnet study
    Publication . Sester, Martina; Altet-Gomez, Neus; Andersen, Åse Bengaard; Arias-Guillén, Miguel; Avsar, Korkut; Bakken Kran, Anne-Marte; Bothamley, Graham; Nordholm Breschel, Anne Christine; Brown, James; Chesov, Dumitru; Ciobanu, Nelly; Cirillo, Daniela Maria; Crudu, Valeriu; de Souza Galvao, Malu; Dilektasli, Asli Görek; Dominguez, José; Duarte, Raquel; Dyrhol-Riise, Anne Ma; Goletti, Delia; Hoffmann, Harald; Ibraim, Elmira; Kalsdorf, Barbara; Krawczyk, Marcin; Kunst, Heinke; Lange, Berit; Lipman, Marc; Matteelli, Alberto; Milkiewicz, Piotr; Neyer, David; Nitschke, Martin; Oral, Haluk Barbaros; Palacios-Gutiérrez, Juan José; Petruccioli, Elisa; Raszeja-Wyszomirska, Joanna; Ravn, Pernille; Rupp, Jan; Spohn, Hanna-Elisa; Toader, Corina; Villar-Hernandez, Raquel; Wagner, Dirk; van Leth, Frank; Martinez, Leonardo; Pedersen, Ole Skouvig; Lange, Christoph
    Background: In low tuberculosis (TB)-endemic countries, tuberculosis preventive therapy (TPT) is recommended for immunocompromised individuals with a positive immunodiagnostic test. This study aimed to assess the performance of the QuantiFERON-TB Gold Plus (QFT+) assay and predictive power for future tuberculosis in immunocompromised individuals. Methods: In this prospective observational study, immunocompromised adults ≥18 years of age including people living with HIV (PLHIV), chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, and immunocompetent adults with and without TB-disease were recruited at 21 sites in 11 European countries and tested with the QFT+ assay. Individuals without TB-disease were followed up for the development of tuberculosis. TB incidence rates (IR) were calculated, stratified by QFT+ results and acceptance of TPT. This study is registered with Clinicaltrials.gov, NCT02639936. Findings: A total of 2663 individuals (1115 female, 1548 male) were enrolled from 03/11/2015 to 29/03/2019. Persons without tuberculosis were followed up for at least two years. Among 1758 immunocompromised individuals without active tuberculosis, 13.6% had positive QFT+ results. Sensitivity and specificity for TB-disease were 70.0% (52.1-83.3%) and 91.4% (89.6-92.9%), respectively, in immunocompromised, and 81.4% (76.6-85.3%) and 96.0% (92.5-97.9%), respectively, in immunocompetent individuals. During 2457 cumulative years of follow-up among 932 individuals with chronic renal failure, rheumatoid arthritis, solid-organ transplantation or stem-cell transplantation, including 83 persons with a positive QFT+ test without TPT, no-one developed active tuberculosis. In contrast, among 642 PLHIV without TPT, one with an indeterminate QFT+ and 3/30 individuals with a positive QFT+ developed active tuberculosis; all had detectable HIV-replication and low CD4 T-cell counts (incidence 4.1 (95% CI (1.3-12.4) per 100 person-years). No individuals receiving TPT developed active tuberculosis during 269 years of follow-up. Interpretation: In immunocompromised individuals in low TB-endemic countries, the 2-year-risk for active tuberculosis was highest among PLHIV with detectable HIV-replication and low CD4-counts. In this study, the QFT+ assay did not strongly predict progression to active tuberculosis, which emphasises the need to incorporate additional risk factors.
    2025-08-06Artigo científico Acesso aberto Ver mais
  • Optimising non-pharmacological interventions in people with non-tuberculous mycobacterial pulmonary disease: a systematic review
    Publication . Sulaiman, Naif; Martins, Beatriz; Moreira-Sousa, Diana; Aguiar, Ana; Hurst, John R.; Brown, James; Duarte, Raquel; Lipman, Marc
    Introduction: Treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) is often complex, relying on long treatment courses with multiple antibiotics, which are associated with treatment intolerance and failure. Current guidelines provide limited insight into non-pharmacological treatment, which is believed to be an important component of symptom control and is related to treatment outcomes with an established evidence base in other chronic respiratory diseases. Methods: The authors conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to identify studies on non-pharmacological interventions for NTM-PD, focusing on airway clearance techniques, pulmonary rehabilitation, nutritional support and psychological care. Results: There was little evidence regarding the impact of non-pharmacological interventions in NTM-PD. We identified three studies that described a positive impact of airway clearance techniques, including oscillating positive expiratory pressure, chest physical therapy with devices such as Acapella and Flutter, as well as chest oscillatory techniques (e.g. Vest) and hypertonic saline nebulisation. We found no relevant studies in NTM-PD reporting the use of nutrition, pulmonary rehabilitation or psychological care as interventions in this group of patients. Conclusions: Non-pharmacological interventions show potential in managing NTM-PD, although significant evidence gaps remain. This review highlights the importance of expanding high-quality studies on the use of these interventions to people with NTM-PD.
    2025-11Artigo científico Acesso aberto Ver mais